ImClone Delays Filing for Added Erbitux Approval

NEW YORK (Reuters) - ImClone Systems Inc. said on Tuesday it will delay seeking U.S. approval for its colon cancer drug, Erbitux, to treat head and neck cancer as it needs more time to analyze data from a pivotal clinical trial.

Continue to ImClone Delays Filing for Added Erbitux Approval on Reuters: Health.

Medical Buzz delivers the most recent headlines from the medical world. Diseases, cures, accidents, medicin. Click below for more headlines ...
Medical buzz